Selective Estrogen Receptor Modulators (SERMs): Advances, Challenges, and Future Prospects in ER+ Breast Cancer...

Area of Science:

• Pharmacology
• Oncology
• Medicinal Chemistry

Background:

• Selective estrogen receptor modulators (SERMs) are crucial for treating estrogen-driven breast cancer.
• SERMs act as estrogen antagonists in breast tissue but agonists in bone and cardiovascular system (CVS).
• Estrogen-receptor-positive breast cancer is the most common subtype globally.

Purpose of the Study:

• To provide a comprehensive analysis of emerging heterocyclic SERMs beyond traditional scaffolds.
• To link chemical diversity with tissue-selective mechanisms and structure-activity relationships.
• To highlight innovative strategies for overcoming limitations and improving therapeutic outcomes.

Main Methods:

• Review of emerging heterocyclic SERM scaffolds (indole, benzimidazole, coumarin, benzopyran, organometallic, phytoestrogen derivatives).
• Analysis of tissue-selective mechanisms and structure-activity relationships.
• Integration of structural, mechanistic, and therapeutic insights.

Main Results:

• Identified limitations of current SERMs: incomplete selectivity, metabolic instability, partial agonism, and endocrine resistance.
• Highlighted novel heterocyclic SERMs with potential for improved efficacy.
• Discussed innovative strategies to overcome resistance and enhance potency.

Conclusions:

• Emerging heterocyclic SERMs represent a promising avenue for ER-positive breast cancer therapy.
• Addressing limitations like resistance and selectivity is key to optimizing clinical outcomes.
• Combination therapies and computational design offer pathways to improved treatment strategies.